Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Chubb
Mallinckrodt
Colorcon
Daiichi Sankyo
Express Scripts
US Army
Julphar
McKesson
Boehringer Ingelheim

Generated: September 25, 2018

DrugPatentWatch Database Preview

ULTRAVATE Drug Profile

« Back to Dashboard

Which patents cover Ultravate, and what generic alternatives are available?

Ultravate is a drug marketed by Sun Pharm Inds Inc and Sun Pharm Industries and is included in three NDAs. There is one patent protecting this drug.

The generic ingredient in ULTRAVATE is halobetasol propionate. There are nine drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the halobetasol propionate profile page.

Drug patent expirations by year for ULTRAVATE
Pharmacology for ULTRAVATE
Synonyms for ULTRAVATE
(1R,8S,13S,14R)-14-(2-chloroacetyl)-1,8-difluoro-17-hydroxy-2,13,15-trimethyl-5-oxotetracyclo[8.7.0.0;{2,7}.0;{11,15}]heptadeca-3,6-dien-14-yl propanoate
(1R,8S,13S,14R)-14-(2-CHLOROACETYL)-1,8-DIFLUORO-17-HYDROXY-2,13,15-TRIMETHYL-5-OXOTETRACYCLO[8.7.0.0(2),?.0(1)(1),(1)?]HEPTADECA-3,6-DIEN-14-YL PROPANOATE
(6|A,11|A,16|A)-21-Chloro-6,9-difluoro-11-hydroxy-16-methyl-17-(1-oxopropoxy)pregna-1,4-diene-3,20-dione
(6|A,11|A,16|A)-21-Chloro-6,9-difluoro-11-hydroxy-16-methyl-17-(1-oxopropoxy)pregna-1,4-diene-3,20-dione; Miracorten; Ulobetasol propionate; Ultravate
(6S,8S,9R,10S,11S,13S,14S,16S,17R)-17-(2-chloroacetyl)-6,9-difluoro-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-17-yl propionate
[(6S,8S,9R,10S,11S,13S,14S,16S,17R)-17-(2-chloroacetyl)-6,9-difluoro-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] propanoate
[(6S,9R,16S,17R)-17-(2-chloroacetyl)-6,9-difluoro-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] propanoate
[17-(2-chloroacetyl)-6,9-difluoro-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] propanoate
21-Chloro-6alpha,9-difluoro-11beta,17-dihydroxy-16beta-methylpregna-1,4-diene-3,20-dione 17-propionate
6 alpha-fluoroclobetasol 17-propionate
6-fluoroclobetasol 17-propionate
66852-54-8
852H548
91A0K1TY3Z
AB01566925_01
AB2000750
AC1L2JJ6
AC1NBUQD
AC1OCF43
AKOS025310143
AN-14228
API0002882
AS-14150
BDSYKGHYMJNPAB-LICBFIPMSA-N
BMY 30056
BMY-30056
C25H31ClF2O5
CAS-66852-54-8
CGP 14 458
CGP 14458
CGP-14,458
CGP-14458
CHEBI:135782
CHEMBL1200908
CHEMBL1876307
CS-4305
CTK8G0126
D00XPC
D04409
DR002999
DSSTox_CID_26636
DSSTox_GSID_46636
DSSTox_RID_81782
DTXSID6046636
FT-0630768
Halobetasol (propionate)
HALOBETASOL PROPIONATE
Halobetasol propionate (USAN)
Halobetasol propionate [USAN:USP]
Halobetasol propionate [USAN]
Halobetasol(propionate)
Halobetasolpropionate
HY-B0878
K097
KS-00001F9L
LS-118431
Miracorten
MolPort-006-167-587
MolPort-023-278-129
NCGC00167451-01
PL066286
Pregna-1,4-diene-3,20-dione, 21-chloro-6,9-difluoro-11-hydroxy-16-methyl-17-(1-oxopropoxy)-, (6alpha,11beta,16beta)-
Pregna-1,4-diene-3,20-dione, 21-chloro-6,9-difluoro-11-hydroxy-16-methyl-17-(1-oxopropoxy)-,(6-alpha,11-beta,16-beta)-
s4089
SC-18329
SCHEMBL1650038
SCHEMBL33858
SR-01000942239
SR-01000942239-1
Tox21_112455
Ulobetasol (Halobetasol)Propionate
Ulobetasol cream
Ulobetasol propionate
Ultravate (TN)
UNII-91A0K1TY3Z
ZINC3920028

US Patents and Regulatory Information for ULTRAVATE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sun Pharm Inds Inc ULTRAVATE halobetasol propionate CREAM;TOPICAL 019967-001 Dec 27, 1990 AB RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Sun Pharm Inds Inc ULTRAVATE halobetasol propionate OINTMENT;TOPICAL 019968-001 Dec 17, 1990 AB RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Sun Pharm Industries ULTRAVATE halobetasol propionate LOTION;TOPICAL 208183-001 Nov 6, 2015 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Sun Pharm Industries ULTRAVATE halobetasol propionate LOTION;TOPICAL 208183-001 Nov 6, 2015 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for ULTRAVATE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sun Pharm Inds Inc ULTRAVATE halobetasol propionate CREAM;TOPICAL 019967-001 Dec 27, 1990 ➤ Sign Up ➤ Sign Up
Sun Pharm Inds Inc ULTRAVATE halobetasol propionate OINTMENT;TOPICAL 019968-001 Dec 17, 1990 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chubb
Mallinckrodt
Colorcon
Daiichi Sankyo
Express Scripts
US Army
Julphar
McKesson
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.